Chester County News and Community Website
WILMINGTON, DE — Vasco Electronics is heading into CES 2026 with an expanded slate of AI-driven tools aimed at redefining how people and organizations communicate across languages, unveiling new software …
Vasco Bets Big on AI to Break Language Barriers at CES 2026 Read More
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has resubmitted its biologics license application for MOLBREEVI to the U.S. Food and Drug Administration, a key regulatory step toward approval …
FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease Read More
WILMINGTON, DE — A $30 million federal research initiative is taking aim at one of drug development’s most stubborn and costly blind spots: predicting how the human heart will respond …
Virtual Hearts, Real Stakes: $30M ARPA-H Bet Targets Drug Cardiac Risk Read More
WILMINGTON, DE — AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) said their jointly developed breast cancer therapy ENHERTU has received Breakthrough Therapy Designation from the U.S. Food and Drug …
ENHERTU Scores Tenth FDA Fast-Track as Breast Cancer Data Shifts Playbook Read More
WILMINGTON, DE — Phreesia (NYSE: PHR) has been named one of The Software Report’s Top 50 Software Companies of 2025, marking its fourth consecutive appearance on the list and its …
Phreesia Cracks Top 10 as Software Recognition Signals Healthcare AI Momentum Read More
WILMINGTON, DE — Incyte (Nasdaq: INCY) said it will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, placing the biopharmaceutical company in front of …
Incyte Takes JPMorgan Stage as Investors Look for Pipeline Signals Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) said the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma, introducing …
Europe Approves Incyte’s Dual-Target Lymphoma Therapy, Expanding Options Read More WILMINGTON, DE — AstraZeneca PLC (NASDAQ: AZN) and Japan’s Daiichi Sankyo said the U.S. Food and Drug Administration has approved ENHERTU in combination with pertuzumab as a first-line treatment for …
FDA Clears ENHERTU Combo as First-Line Breakthrough in HER2 Breast Cancer Read More
WILMINGTON, DE — JPMorgan Chase & Co. (NYSE: JPM) said Chase Freedom and Freedom Flex cardmembers will be able to earn 5% cash back on select rotating categories during the …
Chase Dangles 5% Cash Back on Dining, Cruises, and Charity in 2026 Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) said Hervé Hoppenot recently resigned from its board of directors, effective immediately, formally ending a transition period that followed his long tenure as the …
Incyte Board Exit Closes an Era for the Biotech’s Longtime Leader Read More